Shield Therapeutics share price hits a new 52 week high

Shield Therapeutics share price hits a new 52 week high

Article image

Shares in Shield Therapeutics (LON:STX) are currently trading at a 52 week high, with the share price up by around 16.3% to 99p over the past week. On a one-month basis, the Shield Therapeutics price has risen by 47.1%

Shield is a commercial stage pharma company with a focus on iron deficiency treatments. Last month it said the Swiss Agency for Therapeutic Products had approved a major extension of its lead product, Feraccru to include treatment of all adults with iron deficiency with or without anaemia.

For investors holding the stock (or considering buying it), the question is:what now?

52 week highs are a popular market indicator. Yet research shows investors can be left wondering whether to sell the stock and take a profit or buy more and ride the uptrend. With this in mind, here’s a primer on what you should know about stocks hitting ‘new highs’...

Making sense of 52 week highs

52 week highs are always good news. But you might be surprised to know that the prices of high performing shares can be slow to move when these companies publish positive earnings news.

Studies show it happens because investors are wary about bidding high performing shares any higher (even if they deserve it).

This unusual behaviour is down to what the psychologists Amos Tversky and Daniel Kahneman called anchoring-and-adjustment. We form beliefs by using reference points (like share prices). But as new information comes to light (like earnings reports) we're often slow to update our beliefs away from the original anchor point.

Evidence shows this tug-of-war usually ends with the ‘new high’ stock actually drifting higher in price over the coming weeks and months. The upward trend is called “post earnings announcement drift”. As the news sinks in, momentum takes over and the price moves higher.

A look at Shield Therapeutics’s StockReport could offer more insight into what’s driving the momentum in its share price - and whether that might continue.


What does this mean for potential investors?

With Shield Therapeutics trading close to a 52 week high, it’s possible that investors in the market are uncertain about where the price will move next. It's important to remember that momentum on its own is no guarantee of future returns.

To get a better idea about whether this trend will continue, it's worth doing some investigation yourself. Indeed, we've identified some areas of concern with Shield Therapeutics that you can find out about here.


About us

Stockopedia helps individual investors make confident, profitable choices in the stock market. Our StockRank and factor investing toolbox unlocks institutional-quality insights into thousands of global stocks. Voted “Best Investment Research Tools” and “Best Research Service” at the 2021 UK Investor Magazine awards.

Shield Therapeutics's StockRank™

Sucker StockHighly Speculative

Shield Therapeutics's StockRank™

With a StockRank of 16, Shield Therapeutics is in the bottom 15% of the 7,586 stocks we cover in Europe, according to our proprietary ranking system.

See the full StockReport

Absolutely Perfect

"Trialed multiple other platforms - this is by far my favourite. Other platforms do not even have half the stuff that you can find on Stockopedia. Love it!"

As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.